Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! Please be sure to document all clinical activities daily.
Due tonational shortageof the nebulization solutions, theformulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products willautomatically return to their original formulary status. SeeAlbuterol/Duoneb Shortage Mitigationfor more information. (UpdatedFeb 2023)
Breztri is classified as non-formulary.
Interchange Breztri (160 mcg-9 mcg-4.8 mcg) twice daily to DUONEB (3 mg-0.5 mg/3 mL) four times daily and budesonide nebulization (0.5 mg/2 mL) twice daily.
Due to national shortage of the nebulization solutions, the formulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products will automatically return to their original formulary status. See Albuterol/Duoneb Shortage Mitigation for more information. (Updated Feb 2023)
Breztri is classified as non-formulary.
Interchange Breztri (160 mcg-9 mcg-4.8 mcg) twice daily to DUONEB (3 mg-0.5 mg/3 mL) four times daily and budesonide nebulization (0.5 mg/2 mL) twice daily.
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
Breztri
Duoneb
AND
budesonide nebulization
Reviewed: December 2021 (Breztri)